Research Article
No access
Published Online: 14 June 2010

Proceedings from the Scientific Symposium: Sex Differences in Cardiovascular Disease and Implications for Therapies

Publication: Journal of Women's Health
Volume 19, Issue Number 6

Abstract

A consortium of investigator-thought leaders was convened at the Heart Institute at Cedars-Sinai Medical Center and produced the following summary points:
Point 1: Important sex differences exist in cardiovascular disease (CVD) that affect disease initiation, diagnosis, and treatment.
Implication: Research that acknowledges these differences is needed to optimize outcomes in women and men.
Point 2: Atherosclerosis is qualitatively and quantitatively different in women and men; women demonstrate more plaque erosion and more diffuse plaque with less focal artery lumen intrusion.
Implication: Evaluation of CVD strategies that include devices should be used to explore differing anatomical shapes and surfaces as well as differing drug coating and eluting strategies.
Point 3: Bone marrow progenitor cells (PCs) engraft differently based on the sex of the donor cell and the sex of the recipient.
Implication: PC therapeutic studies need to consider the sex of cells of the source and the recipient.
Point 4: Women have a greater risk of venous but not arterial thrombosis compared with men, as well as more bleeding complications related to anticoagulant treatment. Several genes coding for proteins involved in hemostasis are regulated by sex hormones.
Implications: Research should be aimed at evaluation of sex-based differences in response to anticoagulation based on genotype.
Point 5: Women and men can have differences in pharmacological response.
Implication: Sex-specific pharmacogenomic studies should be included in pharmacological development.
Point 6: CVD progression results from an imbalance of cell injury and repair in part due to insufficient PC repair, which is affected by sex differences, where females have higher circulating levels of PCs with greater rates of tissue repair.
Implication: CVD regenerative strategies should be directed at learning to deliver cells that shift the recipient balance from injury toward repair. CVD repair strategies should ideally be tested first in females to have the best chance of success for proof-of-concept.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Exploring the biological contributions to human health. Does sex matter?J Womens Health Gend Based Med200110433-439. 1. Exploring the biological contributions to human health: Does sex matter? J Womens Health Gend Based Med 2001;10:433–439.
2.
Shaywitz BAShaywitz SEPugh KR et al. Sex differences in the functional organization of the brain for languageNature1995373607-609. 2. Shaywitz BA, Shaywitz SE, Pugh KR, et al. Sex differences in the functional organization of the brain for language. Nature 1995;373:607–609.
3.
Fillingim RBMaixner W. Gender differences in the responses to noxious stimuliPain Forum19954209-221. 3. Fillingim RB, Maixner W. Gender differences in the responses to noxious stimuli. Pain Forum 1995;4:209–221.
4.
Stoverinck MJLagro-Janssen ALWeel CV. Sex differences in health problems, diagnostic testing, and referral in primary careJ Fam Pract199643567-576. 4. Stoverinck MJ, Lagro-Janssen AL, Weel CV. Sex differences in health problems, diagnostic testing, and referral in primary care. J Fam Pract 1996;43:567–576.
5.
Ford ESCapewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: Concealed leveling of mortality ratesJ Am Coll Cardiol2007502128-2132. 5. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: Concealed leveling of mortality rates. J Am Coll Cardiol 2007;50:2128–2132.
6.
Shaw LJBairey Merz CNPepine CJ et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategiesJ Am Coll Cardiol200647Suppl 3S4-S20. 6. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47(Suppl 3):S4–S20.
7.
Bairey Merz CNJohnson BDSharaf BL et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-sponsored WISE studyJ Am Coll Cardiol200341413-419. 7. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003;41:413–419.
8.
Shaw LJBairey Merz CNAzziz R et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome EvaluationJ Clin Endocrinol Metab2008931276-1284. 8. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276–1284.
9.
Ding ELSong YMalik VSLiu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysisJAMA20062951288-1299. 9. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006;295:1288–1299.
10.
Kung HHoyert DXU JMurphy S. Deaths: Final data for 2005National Vital Statistics Reports200856. 10. Kung H, Hoyert D, XU J, Murphy S. Deaths: Final data for 2005. National Vital Statistics Reports 2008;56.
11.
Wong NDPio JValencia RThakal G. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) IIIPrev Cardiol20014109-114. 11. Wong ND, Pio J, Valencia R, Thakal G. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol 2001;4:109–114.
12.
Burke APFarb AMalcom GTLiang YSmialek JVirmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in womenCirculation1998972110-2116. 12. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998;97:2110–2116.
13.
Bairey Merz CNShaw LJReis SE et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: Part II: Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary diseaseJ Am Coll Cardiol200647Suppl 3S21-S29. 13. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: Part II: Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006;47(Suppl 3):S21–29.
14.
Reynolds HRFarkouh MELincoff AM et al. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO VArch Intern Med20071672054-2060. 14. Reynolds HR, Farkouh ME, Lincoff AM, et al. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med 2007;167:2054–2060.
15.
Bellasi ALacey CTaylor AJ et al. Comparison of prognostic usefulness of coronary artery calcium in men versus women (results from a meta- and pooled analysis estimating all-cause mortality and coronary heart disease death or myocardial infarction)Am J Cardiol2007100409-414. 15. Bellasi A, Lacey C, Taylor AJ, et al. Comparison of prognostic usefulness of coronary artery calcium in men versus women (results from a meta- and pooled analysis estimating all-cause mortality and coronary heart disease death or myocardial infarction). Am J Cardiol 2007;100:409–414.
16.
Raggi PShaw LJBerman DSCallister TQ. Gender-based differences in the prognostic value of coronary calcificationJ Womens Health200413273-283. 16. Raggi P, Shaw LJ, Berman DS, Callister TQ. Gender-based differences in the prognostic value of coronary calcification. J Womens Health 2004;13:273–283.
17.
Hemingway HLangenberg CDamant JFrost CPyorala KBarrett-Connor E. Prevalence of angina in women versus men: A systematic review and meta-analysis of international variations across 31 countriesCirculation20081171526-1536. 17. Hemingway H, Langenberg C, Damant J, Frost C, Pyorala K, Barrett-Connor E. Prevalence of angina in women versus men: A systematic review and meta-analysis of international variations across 31 countries. Circulation 2008;117:1526–1536.
18.
Anderson RDPepine CJ. Gender differences in the treatment for acute myocardial infarction: Bias or biology?Circulation2007115823-826. 18. Anderson RD, Pepine CJ. Gender differences in the treatment for acute myocardial infarction: Bias or biology? Circulation 2007;115:823–826.
19.
Shaw LJShaw REMerz CN et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data RegistryCirculation20081171787-1801. 19. Shaw LJ, Shaw RE, Merz CN, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008;117:1787–1801.
20.
Bugiardini RManfrini ODe Ferrari GM. Unanswered questions for management of acute coronary syndrome: Risk stratification of patients with minimal disease or normal findings on coronary angiographyArch Intern Med20061661391-1395. 20. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: Risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006;166:1391–1395.
21.
Vaccarino VParsons LEvery NRBarron HVKrumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 ParticipantsN Engl J Med1999341217-225. 21. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999;341:217–225.
22.
Shaw LJMerz CNPepine CJ et al. The economic burden of angina in women with suspected ischemic heart disease: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome EvaluationCirculation2006114894-904. 22. Shaw LJ, Merz CN, Pepine CJ, et al. The economic burden of angina in women with suspected ischemic heart disease: Results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Circulation 2006;114:894–904.
23.
Hemingway HMAShipley MManderbacka KMartikainen PKeskimaki I. Incidence and prognostic implications of stable angina pectoris among women and menJAMA20062951404-1411. 23. Hemingway HMA, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 2006;295:1404–1411.
24.
Wiviott SDCannon CPMorrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudyCirculation2004109580-586. 24. Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 2004;109:580–586.
25.
Sekhri NFeder GSJunghans C et al. Incremental prognostic value of the exercise electrocardiogram in the initial assessment of patients with suspected angina: Cohort studyBMJ2008337a2240. 25. Sekhri N, Feder GS, Junghans C, et al. Incremental prognostic value of the exercise electrocardiogram in the initial assessment of patients with suspected angina: Cohort study. BMJ 2008;337:a2240.
26.
Glagov SWeisenberg EZarins CKStankunavicius RKolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteriesN Engl J Med19873161371-1375. 26. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371–1375.
27.
Shah PK. Molecular mechanisms of plaque instabilityCurr Opin Lipidol200718492-499. 27. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007;18:492–499.
28.
Farb ABurke APTang AL et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary deathCirculation1996931354-1363. 28. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354–1363.
29.
Sugiyama SKugiyama KAikawa MNakamura SOgawa HLibby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of yeloperoxidase-mediated oxidant in plaque erosion and thrombogenesisArterioscler Thromb Vasc Biol2004241309-1314. 29. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of yeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309–1314.
30.
Durand EScoazec ALafont A et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: A clue to the understanding of the mechanisms of thrombotic plaque erosionCirculation20041092503-2506. 30. Durand E, Scoazec A, Lafont A, et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: A clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 2004;109:2503–2506.
31.
Sambola AOsende JHathcock J et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicityCirculation2003107973-977. 31. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003;107:973–977.
32.
Kar SShah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque ruptureRev Cardiovasc Med20012215-219. 32. Kar S, Shah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. Rev Cardiovasc Med 2001;2:215–219.
33.
Prasad ALerman ARihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): A mimic of acute myocardial infarctionAm Heart J2008155408-417. 33. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): A mimic of acute myocardial infarction. Am Heart J 2008;155:408–417.
34.
Singh VMayer TSalanitri JSalinger MH. Cardiac MRI documented left ventricular thrombus complicating acute Takotsubo syndrome: An uncommon dilemmaInt J Cardiovasc Imaging2007235591-593. 34. Singh V, Mayer T, Salanitri J, Salinger MH. Cardiac MRI documented left ventricular thrombus complicating acute Takotsubo syndrome: An uncommon dilemma. Int J Cardiovasc Imaging 2007;23(5):591–593.
35.
Lyon ARRees PSPrasad SPoole-Wilson PAHarding SE. Stress (Takotsubo) cardiomyopathy—A novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunningNat Clin Pract Cardiovasc Med2008522-29. 35. Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy—A novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008;5:22–29.
36.
Turner CHSun QSchriefer J et al. Congenic mice reveal sex-specific genetic regulation of femoral structure and strengthCalcif Tissue Int200373297-303. 36. Turner CH, Sun Q, Schriefer J, et al. Congenic mice reveal sex-specific genetic regulation of femoral structure and strength. Calcif Tissue Int 2003;73:297–303.
37.
Kinney RCSchwartz ZWeek KLotz MKBoyan BD. Human articular chondrocytes exhibit sexual dimorphism in their responses to 17beta-estradiolOsteoarthritis Cartilage200513330-337. 37. Kinney RC, Schwartz Z, Week K, Lotz MK, Boyan BD. Human articular chondrocytes exhibit sexual dimorphism in their responses to 17beta-estradiol. Osteoarthritis Cartilage 2005;13:330–337.
38.
McMillan JFatehi-Sedeh SSylvia VL et al. Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathwaysBiochim Biophys Acta20061763381-392. 38. McMillan J, Fatehi-Sedeh S, Sylvia VL, et al. Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim Biophys Acta 2006;1763:381–392.
39.
Raz PNasatzky EBoyan BDOrnoy ASchwartz Z. Sexual dimorphism of growth plate prehypertrophic and hypertrophic chondrocytes in response to testosterone requires metabolism to dihydrotestosterone (DHT) by steroid 5-alpha reductase type 1J Cell Biochem200595108-119. 39. Raz P, Nasatzky E, Boyan BD, Ornoy A, Schwartz Z. Sexual dimorphism of growth plate prehypertrophic and hypertrophic chondrocytes in response to testosterone requires metabolism to dihydrotestosterone (DHT) by steroid 5-alpha reductase type 1. J Cell Biochem 2005;95:108–119.
40.
Sylvia VLGay IHardin RDean DDBoyan BDSchwartz Z. Rat costochondral chondrocytes produce 17beta-estradiol and regulate its production by 1alpha,25(OH)(2)D(3)Bone20023057-63. 40. Sylvia VL, Gay I, Hardin R, Dean DD, Boyan BD, Schwartz Z. Rat costochondral chondrocytes produce 17beta-estradiol and regulate its production by 1alpha,25(OH)(2)D(3). Bone 2002;30:57–63.
41.
Payne TROshima HSakai T et al. Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cellsGene Ther2005121264-1274. 41. Payne TR, Oshima H, Sakai T, et al. Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells. Gene Ther 2005;12:1264–1274.
42.
Boyan BDLossdorfer SWang L et al. Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographiesEur Cell Mater2003622-27. 42. Boyan BD, Lossdorfer S, Wang L, et al. Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. Eur Cell Mater 2003;6:22–27.
43.
Lohmann CHTandy EMSylvia VL et al. Response of normal female human osteoblasts (NHOst) to 17beta-estradiol is modulated by implant surface morphologyJ Biomed Mater Res200262204-213. 43. Lohmann CH, Tandy EM, Sylvia VL, et al. Response of normal female human osteoblasts (NHOst) to 17beta-estradiol is modulated by implant surface morphology. J Biomed Mater Res 2002;62:204–213.
44.
Sela JShani JKohavi D et al. Uptake and biodistribution of 99mtechnetium methylene-[32P] diphosphonate during endosteal healing around titanium, stainless steel and hydroxyapatite implants in rat tibial boneBiomaterials1995161373-1380. 44. Sela J, Shani J, Kohavi D, et al. Uptake and biodistribution of 99mtechnetium methylene-[32P] diphosphonate during endosteal healing around titanium, stainless steel and hydroxyapatite implants in rat tibial bone. Biomaterials 1995;16:1373–1380.
45.
Boyan BDSchwartz Z. Consideration of systemic hormone status when treating patients with osteopeniaJ Periodontol2003741692-1693. 45. Boyan BD, Schwartz Z. Consideration of systemic hormone status when treating patients with osteopenia. J Periodontol 2003;74:1692–1693.
46.
Shapiro F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblastsEur Cell Mater20081553-76. 46. Shapiro F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 2008;15:53–76.
47.
Bajada SMazakova IRichardson JBAshammakhi N. Updates on stem cells and their applications in regenerative medicineJ Tissue Eng Regen Med20082169-183. 47. Bajada S, Mazakova I, Richardson JB, Ashammakhi N. Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med 2008;2:169–183.
48.
Burke ZDThowfeequ SPeran MTosh D. Stem cells in the adult pancreas and liverBiochem J2007404169-178. 48. Burke ZD, Thowfeequ S, Peran M, Tosh D. Stem cells in the adult pancreas and liver. Biochem J 2007;404:169–178.
49.
Fuchs E. Skin stem cells: Rising to the surfaceJ Cell Biol2008180273-284. 49. Fuchs E. Skin stem cells: Rising to the surface. J Cell Biol 2008;180:273–284.
50.
Huang XCho SSpangrude GJ. Hematopoietic stem cells: Generation and self-renewalCell Death Differ2007141851-1859. 50. Huang X, Cho S, Spangrude GJ. Hematopoietic stem cells: Generation and self-renewal. Cell Death Differ 2007;14:1851–1859.
51.
Kotton DNFine A. Lung stem cellsCell Tissue Res2008331145-156. 51. Kotton DN, Fine A. Lung stem cells. Cell Tissue Res 2008;331:145–156.
52.
Krause DS. Bone marrow-derived cells and stem cells in lung repairProc Am Thorac Soc20085323-327. 52. Krause DS. Bone marrow-derived cells and stem cells in lung repair. Proc Am Thorac Soc 2008;5:323–327.
53.
Schaffer DVGage FH. Neurogenesis and neuroadaptationNeuromolecular Med200451-9. 53. Schaffer DV, Gage FH. Neurogenesis and neuroadaptation. Neuromolecular Med 2004;5:1–9.
54.
Smart NRiley PR. The stem cell movementCirc Res20081021155-1168. 54. Smart N, Riley PR. The stem cell movement. Circ Res 2008;102:1155–1168.
55.
Yen THWright NA. The gastrointestinal tract stem cell nicheStem Cell Rev20062203-212. 55. Yen TH, Wright NA. The gastrointestinal tract stem cell niche. Stem Cell Rev 2006;2:203–212.
56.
Colmegna IDiaz-Borjon AFujii HSchaefer LGoronzy JJWeyand CM. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritisArthritis Rheum200858990-1000. 56. Colmegna I, Diaz-Borjon A, Fujii H, Schaefer L, Goronzy JJ, Weyand CM. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008;58:990–1000.
57.
Rauscher FMGoldschmidt-Clermont PJDavis BH et al. Aging, progenitor cell exhaustion, and atherosclerosisCirculation2003108457-463. 57. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003;108:457–463.
58.
Rossi DJJamieson CHWeissman IL. Stems cells and the pathways to aging and cancerCell2008132681-696. 58. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008;132:681–696.
59.
van Praag HShubert TZhao CGage FH. Exercise enhances learning and hippocampal neurogenesis in aged miceJ Neurosci2005258680-8685. 59. van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 2005;25:8680–8685.
60.
Warren LARossi DJ. Stem cells and aging in the hematopoietic systemMech Ageing Dev200813046-53. 60. Warren LA, Rossi DJ. Stem cells and aging in the hematopoietic system. Mech Ageing Dev 2008;130:46–53.
61.
Zenovich AGTaylor DA. Atherosclerosis as a disease of failed endogenous repairFront Biosci2008133621-3636. 61. Zenovich AG, Taylor DA. Atherosclerosis as a disease of failed endogenous repair. Front Biosci 2008;13:3621–3636.
62.
Nelson WDZenovich AGOtt HC et al. Sex-dependent attenuation of plaque growth after treatment with bone marrow mononuclear cellsCirc Res20071011319-1327. 62. Nelson WD, Zenovich AG, Ott HC, et al. Sex-dependent attenuation of plaque growth after treatment with bone marrow mononuclear cells. Circ Res 2007;101:1319–1327.
63.
Zenovich AGPanoskaltsis-Mortari ACaron GJ et al. Sex-based differences in vascular repair with bone marrow cell therapy: Relevance of regulatory and Th2-type cytokinesTransplant Proc200840641-643. 63. Zenovich AG, Panoskaltsis-Mortari A, Caron GJ, et al. Sex-based differences in vascular repair with bone marrow cell therapy: Relevance of regulatory and Th2-type cytokines. Transplant Proc 2008;40:641–643.
64.
Domecq CNaranjo CARuiz IBusto U. Sex-related variations in the frequency and characteristics of adverse drug reactionsInt J Clin Pharmacol Ther Toxicol198018362-366. 64. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980;18:362–366.
65.
Makkar RRFromm BSSteinman RTMeissner MDLehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugsJAMA19932702590-2597. 65. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590–2597.
66.
Lee PYAlexander KPHammill BGPasquali SKPeterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromesJAMA2001286708-713. 66. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708–713.
67.
Merz CNKelsey SFPepine CJ et al. The Women's Ischemia Syndrome Evaluation (WISE) study: Protocol design, methodology and feasibility reportJ Am Coll Cardiol1999331453-1461. 67. Merz CN, Kelsey SF, Pepine CJ, et al. The Women's Ischemia Syndrome Evaluation (WISE) study: Protocol design, methodology and feasibility report. J Am Coll Cardiol 1999;33:1453–1461.
68.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ200232471-86. 68. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
69.
Boersma EHarrington RAMoliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trialsLancet2002359189-198. 69. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189–198.
70.
Ridker PMCook NRLee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in womenN Engl J Med20053521293-1304. 70. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.
71.
Miettinen TAPyorala KOlsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)Circulation1997964211-4218. 71. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211–4218.
72.
Ridker PMDanielson EFonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med20083592195-2207. 72. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
73.
Murphy S. Death: Final data for 1998National Vital Statistics Reports2000481-105. 73. Murphy S. Death: Final data for 1998. National Vital Statistics Reports 2000;48:1–105.
74.
Ghali JKPina ILGottlieb SSDeedwania PCWikstrand JC. Metoprolol CR/XL in female patients with heart failure: Analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)Circulation20021051585-1591. 74. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: Analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105:1585–1591.
75.
Olsson GWikstrand JWarnold I et al. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trialsEur Heart J19921328-32. 75. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28–32.
76.
Cairns JAConnolly SJRoberts RGent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial InvestigatorsLancet1997349675-682. 76. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675–682.
77.
Doval HCNul DRGrancelli HOPerrone SVBortman GRCuriel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)Lancet1994344493-498. 77. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493–498.
78.
Julian DGCamm AJFrangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial InvestigatorsLancet1997349667-674. 78. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667–674.
79.
Massie BMFisher SGRadford M et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT InvestigatorsCirculation1996932128-2134. 79. Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996;93:2128–2134.
80.
Russo AMStamato NJLehmann MH et al. Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia TrialJ Cardiovasc Electrophysiol200415993-998. 80. Russo AM, Stamato NJ, Lehmann MH, et al. Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. J Cardiovasc Electrophysiol 2004;15:993–998.
81.
Bugiardini RBairey Merz CN. Angina with “normal” coronary arteries: A changing philosophyJAMA2005293477-484. 81. Bugiardini R, Bairey Merz CN. Angina with “normal” coronary arteries: A changing philosophy. JAMA 2005;293:477–484.
82.
Reis SEHolubkov RConrad Smith AJ et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE studyAm Heart J2001141735-741. 82. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. Am Heart J 2001;141:735–741.
83.
Johnson BDShaw LJPepine CJ et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) studyEur Heart J2006271408-1415. 83. Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J 2006;27:1408–1415.
84.
von Mering GOArant CBWessel TR et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE)Circulation2004109722-725. 84. von Mering GO, Arant CB, Wessel TR, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:722–725.
85.
Pepine CKerensky RLambert C et al. Some thoughts on the vasculopathy of women with ischemic heart diseaseJ Am Coll Cardiol20064730-35. 85. Pepine C, Kerensky R, Lambert C, et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol 2006;47:30–35.
86.
Von Mering GOJACC200137Suppl A293A. 86. Von Mering GO. JACC 2001;37(Suppl A):293A.
87.
Kelsey SFJames MHolubkov ALHolubkov RCowley MJDetre KM. Results of percutaneous transluminal coronary angioplasty in women. 1985–1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty RegistryCirculation199387720-727. 87. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM. Results of percutaneous transluminal coronary angioplasty in women. 1985–1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993;87:720–727.
88.
Jacobs AKKelsey SFYeh W et al. Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993–94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). National Heart, Lung, and Blood InstituteAm J Cardiol199780979-984. 88. Jacobs AK, Kelsey SF, Yeh W, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993–94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). National Heart, Lung, and Blood Institute. Am J Cardiol 1997;80:979–984.
89.
Haque SMatsubayashi HIzumi S et al. Sex differences in platelet aggregation detected by new aggregometry using light scatteringEndocr J20014833-41. 89. Haque S, Matsubayashi H, Izumi S, et al. Sex differences in platelet aggregation detected by new aggregometry using light scattering. Endocr J 2001;48:33–41.
90.
Schwertz DWPenckofer S. Sex differences and the effects of sex hormones on hemostasis and vascular reactivityHeart Lung200130401-426. 90. Schwertz DW, Penckofer S. Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung 2001;30:401–426.
91.
Rosamond WFlegal KFurie K et al. Heart disease and stroke statistics—2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation2008117e25-146. 91. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25–146.
92.
Becker RCTerrin MRoss R et al. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction InvestigatorsAnn Intern Med1994120638-645. 92. Becker RC, Terrin M, Ross R, et al. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med 1994;120:638–645.
93.
Kannel WBSorlie PMcNamara PM. Prognosis after initial myocardial infarction: The Framingham studyAm J Cardiol19794453-59. 93. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: The Framingham study. Am J Cardiol 1979;44:53–59.
94.
Mega JLMorrow DAOstor E et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarctionCirculation20071152822-2828. 94. Mega JL, Morrow DA, Ostor E, et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 2007;115:2822–2828.
95.
Berger JSBrown DL. Impact of gender on mortality following primary angioplasty for acute myocardial infarctionProg Cardiovasc Dis200446297-304. 95. Berger JS, Brown DL. Impact of gender on mortality following primary angioplasty for acute myocardial infarction. Prog Cardiovasc Dis 2004;46:297–304.
96.
Cho LTopol EJBalog C et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for StentJ Am Coll Cardiol200036381-386. 96. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000;36:381–386.
97.
Alexander KPChen AYNewby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiativeCirculation20061141380-1387. 97. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006;114:1380–1387.
98.
Hochman JSTamis JEThompson TD et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb InvestigatorsN Engl J Med1999341226-232. 98. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999;341:226–232.
99.
Glaser RHerrmann HCMurphy SA et al. Benefit of an early invasive management strategy in women with acute coronary syndromesJAMA20022883124-3129. 99. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002;288:3124–3129.
100.
Lagerqvist BSafstrom KStahle EWallentin LSwahn E. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group InvestigatorsJ Am Coll Cardiol20013841-48. 100. Lagerqvist B, Safstrom K, Stahle E, Wallentin L, Swahn E. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 2001;38:41–48.
101.
Anderson JLAdams CDAntman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJ Am Coll Cardiol200750e1-e157. 101. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1–e157.
102.
Watanabe CTMaynard CRitchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus womenAm J Cardiol200188848-852. 102. Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol 2001;88:848–852.
103.
Abbott JDVlachos HASelzer F et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry)Am J Cardiol200799626-631. 103. Abbott JD, Vlachos HA, Selzer F, et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007;99:626–631.
104.
Hassan WAl-Sergani HBuraiki JA et al. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) studyAm Heart J2007154345-351. 104. Hassan W, Al-Sergani H, Buraiki JA, et al. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study. Am Heart J 2007;154:345–351.
105.
Stone GWGrines CLBrowne KF et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) trailJ Am Coll Cardiol199525370-377. 105. Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) trail. J Am Coll Cardiol 1995;25:370–377.
106.
Hoetzer GLMacEneaney OJIrmiger HM et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adultsAm J Cardiol20079946-48. 106. Hoetzer GL, MacEneaney OJ, Irmiger HM, et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. Am J Cardiol 2007;99:46–48.
107.
Crisostomo PRWang MHerring CM et al. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: Role of the 55 kDa TNF receptor (TNFR1)J Mol Cell Cardiol200742142-149. 107. Crisostomo PR, Wang M, Herring CM, et al. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: Role of the 55 kDa TNF receptor (TNFR1). J Mol Cell Cardiol 2007;42:142–149.
108.
Crisostomo PRMarkel TAWang MLahm TLillemoe KDMeldrum DR. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective powerSurgery2007142215-221. 108. Crisostomo PR, Markel TA, Wang M, Lahm T, Lillemoe KD, Meldrum DR. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery 2007;142:215–221.
109.
Smith RRBarile LCho HC et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimensCirculation2007115896-908. 109. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896–908.
110.
Takahashi KTanabe KOhnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factorsCell2007131861-872. 110. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872.
111.
Mohyeddin-Bonab MMohamad-Hassani MRAlimoghaddam K et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarctionArch Iran Med200710467-473. 111. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med 2007;10:467–473.

Information & Authors

Information

Published In

cover image Journal of Women's Health
Journal of Women's Health
Volume 19Issue Number 6June 2010
Pages: 1059 - 1072
PubMed: 20500123

History

Published online: 14 June 2010
Published in print: June 2010
Published ahead of print: 26 May 2010

Permissions

Request permissions for this article.

Authors

Affiliations

C. Noel Bairey Merz
Cedars-Sinai Heart Institute, Los Angeles, California.
Saralyn Mark
Yale University, New Haven, Connecticut, and Georgetown University, Washington, District of Columbia.
Barbara D. Boyan
Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, Georgia.
Alice K. Jacobs
Boston University School of Medicine, Boston, Massachusetts.
Prediman K. Shah
Cedars-Sinai Heart Institute, Los Angeles, California.
Leslee J. Shaw
Emory University, Atlanta, Georgia.
Doris Taylor
University of Minnesota, Minneapolis, Minnesota.
Eduardo Marbán
Cedars-Sinai Heart Institute, Los Angeles, California.

Notes

Address correspondence to:C. Noel Bairey Merz, M.D.Women's Heart CenterCedars-Sinai Heart Institute444 S. San Vincente BoulevardLos Angeles, CA 90048E-mail: [email protected]

Disclosure Statement

A.K.J. has stock options at Wyeth and is a research site PI at Abiomed Abbot Vascular Accumetrics. S.M. serves as a part-time consultant in the capacity of senior policy advisor to the Cook Group, Inc.
The authors have no conflicts of interest to report.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top